Annual Report 2022

Annual Report 2022

2023 Outlook

The information below is subject to risks and uncertainties that may materially impact the achievement of our 2023 outlook. For more information, please refer to section ”Risk Factors” of this Annual Report for a discussion of such risks and uncertainties.

Planned Commercial Milestones

VYVGART gMG Approval in China

YE 2023

VYVGART gMG Approval in Canada

3Q 2023

VYVGART gMG Launch in France, UK, Italy

YE 2023

SC efgartigimod gMG PDUFA Date

June 20, 2023

SC efgartigimod gMG Approval in EU

4Q 2023

SC efgartigimod gMG Submission in Japan

1Q 2023

VYVGART ITP Submission in Japan

Mid-2023
See Our Products and Product Candidates

Planned Clinical Milestones

Efgartigimod

ADHERE data in CIDP

2Q 2023

ADDRESS data in Pemphigus

2H 2023

ADVANCE (SC) data in ITP

2H 2023

POC data in Post-COVID POTS

4Q 2023

Initiate registrational trial in TED

4Q 2023

Initiate POC studies in ANCA and AMR

4Q 2023
See Our Products and Product Candidates

Additional pipeline

ARGX-117

ARDA MMN interim results

Mid, 2023

Initiate DGF POC study

2H 2023

ARGX-119

Initiate Phase 1 study

1Q 2023
See Our Products and Product Candidates